Michelle Keefe - 23 Feb 2023 Form 4 Insider Report for Syneos Health, Inc.

Role
Chief Executive Officer, Director
Signature
/s/ Sara Epstein, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
23 Feb 2023
Net transactions value
-$127,678
Form type
4
Filing time
24 Feb 2023, 16:05:53 UTC
Previous filing
19 Jan 2023
Next filing
17 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYNH Class A Common Stock Award $0 +4,627 +2.4% $0.000000 195,473 23 Feb 2023 Direct F1
transaction SYNH Class A Common Stock Award $0 +1,203 +0.62% $0.000000 196,676 23 Feb 2023 Direct F2
transaction SYNH Class A Common Stock Award $0 +3,371 +1.7% $0.000000 200,047 23 Feb 2023 Direct F3
transaction SYNH Class A Common Stock Tax liability $127,678 -3,338 -1.7% $38.25 196,709 23 Feb 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance restricted stock units that were earned based upon performance criteria for the year ended December 31, 2022.
F2 Represents performance restricted stock units that were earned based upon performance criteria for the year ended December 31, 2022 and will vest in full on the date on which the Compensation and Management Development Committee (the "Committee") of the Board of Directors of Syneos Health, Inc. (the "Issuer") determines the attainment level of the performance goals for the year ended December 31, 2023, subject to continued employment.
F3 Represents performance restricted stock units that were earned based upon performance criteria for the year ended December 31, 2022 and will vest in full once the Committee determines the attainment level of the performance goals for the year ended December 31, 2024, subject to continued employment.